Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus multilocularis | SWI:SNF matrix associated | 0.1034 | 0.5 | 0.5 |
Plasmodium vivax | hypothetical protein, conserved | 0.1034 | 0.5 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.1034 | 0.5 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.1034 | 0.5 | 0.5 |
Loa Loa (eye worm) | SWIB/MDM2 domain-containing protein | 0.1034 | 0.5 | 0.5 |
Echinococcus multilocularis | SWI:SNF matrix associated | 0.1034 | 0.5 | 0.5 |
Onchocerca volvulus | 0.1034 | 0.5 | 0.5 | |
Echinococcus granulosus | SWI:SNF matrix associated | 0.1034 | 0.5 | 0.5 |
Trichomonas vaginalis | conserved hypothetical protein | 0.1034 | 0.5 | 0.5 |
Chlamydia trachomatis | DNA topoisomerase I | 0.1034 | 0.5 | 0.5 |
Brugia malayi | SWIB/MDM2 domain containing protein | 0.1034 | 0.5 | 0.5 |
Schistosoma mansoni | brg-1 associated factor | 0.1034 | 0.5 | 0.5 |
Echinococcus multilocularis | Upstream activation factor subunit UAF30 | 0.1034 | 0.5 | 0.5 |
Chlamydia trachomatis | SWIB complex protein | 0.1034 | 0.5 | 0.5 |
Plasmodium falciparum | SWIB/MDM2 domain-containing protein | 0.1034 | 0.5 | 0.5 |
Brugia malayi | brahma associated protein 60 kDa | 0.1034 | 0.5 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.1034 | 0.5 | 0.5 |
Echinococcus granulosus | Upstream activation factor subunit UAF30 | 0.1034 | 0.5 | 0.5 |
Toxoplasma gondii | SWIB/MDM2 domain-containing protein | 0.1034 | 0.5 | 0.5 |
Plasmodium vivax | SWIB/MDM2 domain-containing protein, putative | 0.1034 | 0.5 | 0.5 |
Loa Loa (eye worm) | brahma associated protein | 0.1034 | 0.5 | 0.5 |
Plasmodium falciparum | SWIB/MDM2 domain-containing protein | 0.1034 | 0.5 | 0.5 |
Toxoplasma gondii | DNA topoisomerase domain-containing protein | 0.1034 | 0.5 | 0.5 |
Echinococcus multilocularis | SWI:SNF matrix associated | 0.1034 | 0.5 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
GI50 (functional) | -4.363 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the HOP-92 Non-Small Cell Lung cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4.276 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-5 Melanoma cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4.222 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the MALME-3M Melanoma cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4.115 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the UO-31 Renal cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SN12C Renal cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the NCI-H23 Non-Small Cell Lung cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the ACHN Renal cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the HL-60(TB) Leukemia cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SF-539 Central Nervous System cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.